Who We Are

ETERN is an innovative biotech company focused on the research and development of small molecule drugs targeting protein liquid-liquid phase separation.

“Undruggable” Targets

LLPS Technology Platform

ETERN has pioneered a state-of-the-art protein liquid-liquid phase separation technology platform that seamlessly integrates AI-assisted phase separation target discovery, high-throughput and high-content drug screening, and drug optimization techniques. The development of small-molecule drugs that effectively regulate protein liquid-liquid phase separation holds immense promise in paving the way for novel therapeutic modalities against a diverse range of challenging targets that are yet to be addressed by conventional drug discovery.